CellCentric
Develops inobrodib, a first-in-class oral p300/CBP inhibitor for relapsed or refractory multiple myeloma
$220MSeries D
Role not disclosedLoading investors…
Activity from announced rounds
Develops inobrodib, a first-in-class oral p300/CBP inhibitor for relapsed or refractory multiple myeloma
Develops novel drug discovery platform to target epigenetic targets in pediatric brain cancer
Pitching American Cancer Society BrightEdge? Send the deck from a free RoundOS data room and see which pages they read.
Create a free room